ADAM9 and hepatocellular carcinoma: The combination of regorafenib and an ADAM9 enzymatic inhibitor strongly inhibited MICA shedding than either of the agents alone [78], and the consequent accumulation of mMICA augmented NK cell cytotoxicity against human HCC cells [10].